The prognosis of peripheral T-cell lymphoma patients is significantly poor, and high intratumoral galectin-1 expression before treatment was associated with adverse outcomes in a cohort of patients with CD30+ and ALK− peripheral T-cell lymphoma (106). The gene discussed is TNFRSF8; the disease is peripheral T-cell lymphoma, not otherwise specified.